Novel Agents for Gram-Negative Biodefense Pathogens Final Report CRADA No. TC02128.0

Technical Report · Wed Jan 31 04:00:00 EST 2018

DOI:https://doi.org/10.2172/1424632· OSTI ID:1424632

Finn, J. ^[1]; Lightstone, F. ^[2]; Turteltaub, K. W. ^[2]

---

1. Trius Theraputics, San Diego, CA (United States)
2. Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)

This was a collaborative effort between Lawrence Livermore National Security, LLC as manager and operator of Lawrence Livermore National Laboratory (LLNL) and Trius Therapeutics, Inc. ("Trius") to develop novel agents for gram-negative biodefense pathogens. LLNL and Trius jointly responded to a U.S. Health and Human Services (National Institutes of Health) request for proposals (solicitation # BAA NIH-NIAID-DMID 08-20) to develop new therapeutic countermeasures with a proposal entitled "Development of Therapeutic Agents for Select Biodefense Pathogens" which resulted in this CRADA, with a goal of developing gram-negative, dual-target antibacterial agents that show no cross-resistance to existing drugs. Trius was awarded Contract HHSN272200800042C to accomplish the goals in the proposal, with LLNL as a major subcontractor.

• Research Organization: Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States)
• Sponsoring Organization: USDOE
• DOE Contract Number: AC52-07NA27344
• OSTI ID: 1424632
• Report Number(s): LLNL--TR-745528; LLNL-TR-638984
• Country of Publication: United States
• Language: English

Related Subjects

59 BASIC BIOLOGICAL SCIENCES